Additional analysis of visual acuity loss, genotypic profiles, and retinal imaging data from a 24-month Phase 2 trial of Tinlarebant in adolescent Stargardt disease patients provides further support ...
Belite Bio completes enrollment in phase 2/3 DRAGON II clinical trial evaluating tinlarebant for the treatment of Stargardt disease type 1 (STGD1). Belite Bio has completed enrollment in its phase 2/3 ...
Please provide your email address to receive an email when new articles are posted on . The study met its primary endpoint, and patients who received gildeuretinol (Alkeus Pharmaceuticals) showed a ...
Established Low Dose as Safe and Tolerable Dose in Current OCU410ST Clinical Trial DSMB Determination to Proceed with Medium Dose Cohort Dosing MALVERN, Pa., April 01, 2024 (GLOBE NEWSWIRE) -- Ocugen, ...
Designations underscore significant unmet need in Stargardt disease, a rare and serious pediatric disease for which no treatment exists. Data from Alkeus’ TEASE program were presented at the American ...
DALLAS, Aug. 14, 2025 /PRNewswire/ -- Nanoscope Therapeutics Inc., a biotechnology company committed to developing and commercializing novel gene-agnostic therapies for patients suffering vision loss ...
MALVERN, Pa., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and ...
Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...
Belite Bio Inc. unveiled positive top-line data from the 104-subject phase III Dragon study with tinlarebant in Stargardt disease type 1 (STGD1). The trial met its primary efficacy endpoint, turning ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results